CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin.

ABSTRACT:

Background

The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity in adult cohorts.

Objectives

This study evaluated the presence of associations between CBR3 V244M genotype status and changes in echocardiographic parameters in breast cancer patients undergoing doxorubicin treatment.

Methods

We recruited 155 patients with breast cancer receiving treatment with doxorubicin (DOX) at Roswell Park Comprehensive Care Center (Buffalo, NY) to a prospective single arm observational pharmacogenetic study. Patients were genotyped for the CBR3 V244M variant.

SUBMITTER: Lang JK 

PROVIDER: S-EPMC8111996 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature